Page 168 - Molecular features of low-grade developmental brain tumours

6
166
CHAPTER 6
and could prevent unnecessary treatment with chemo-radiation therapy. However, to determine the diagnostic value of these molecular markers in distinguishing GGs from DNTs, these miRNAs need to be validated in larger multicenter cohorts that include difficult-to- classify LEAT subtypes.
Author Contributions
EA conceived the study and participated in its design and coordination together with AI, AM and EV. FJ, WS, MT, RC, IB, KK, SJ, WG, FS, JP, AM and EA contributed to the collection and selection of tissue samples and/or clinical data. AB and AP conducted and analysed most of the experiments, supported by AA, JA and RR. AB, AP, JM, EA, AS, AM and EV wrote the manuscript. All authors read and approved the final manuscript.
Acknowledgements
We are grateful to Dr Chris Jones (Institute of Cancer Research, Sutton, UK) for providing the human pediatric low grade astrocytoma cell line (WHO grade II: Res-259).
Funding
This work was supported by KIKA (Stichting Kinderen Kankervrij; AB, AP, EA); Stichting AMC Foundation (EA, EV); Stichting Knip Fonds and TSC Fonds (EA); the Austrian Science Fund (FWF, no. J3499; AM); the European Union 7th framework program: acronym EPISTOP (grant agreement no. 602391; FJ, SJ, AM, EA); the European Union 7th framework program: acronym DESIRE (grant agreement no. 602531; IB); the Polish Ministerial funds for science (years 2013-2018) for the implementation of international co-financed project (KK, SJ) and internal research project of the Children’s Memorial Health Institute no.S132/2013 (KK, SJ).
Conflicts of Interest
None of the authors has any conflict of interest to disclose. We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.